WUXIF News and Press, Wuxi AppTec Co. Ltd. - Class H From 10/16/22

Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...

Summary Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment. Nanjing Frontier Biotechnologies completed a $29 million private placemen...

Frontera Therapeutics completed a $160 million Series B funding to support its AAV programs. Merck KGaA announced its Uptune program will back Asia startup companies with up to €100,000 each to advance their projects into proof-of-concept studies. Shanghai Antengene will co...

Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...

Harding Loevner has been investing globally in high-quality, growing businesses based on disciplined industry research since 1989. Emerging Markets (EMs) declined sharply, primarily due to the collapse in Russian equities brought about by economic sanctions against Russia because of i...

Wuhan Binhui Biopharm closed a $47 million Series B financing to support its R&D of oncolytic virus products. Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca drugs. Hangzhou Asc...

The CXO giant announced it expects to post record-high revenue in the first quarter of 2022. WuXi AppTec said it expects year-on-year revenue growth of 65% to 68% in the first quarter of this year. The provider of drug development services is ranked relatively weaker than its peer...

Concord, Mass.-based Adiso Therapeutics, an anti-inflammatory biotech, officially emerged from stealth mode with backing from Hong Kong's Morningside Ventures. Morningside has already invested $60 million in the company and has another $35 million earmarked for the company's B round. ...

France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO. Sinovac Biotech reported that a third dose of its inac...

Healthcare was the second-best performing sector in China in 2020. The immediate healthcare needs stemming from the pandemic, together with the emergence of green shoots in biotech innovation, paved the way for a landmark year in the development of China’s healthcare system. ...